Emelie Svanberg

Senior Associate
  • Stockholm
  • Languages:
    Swedish, English

Practice Areas

Education

  • Uppsala University, LL.M., 2018
  • Vienna University of Business and Economics, exchange semester, 2017
  • University of Victoria, exchange semester, 2016

Mandates

Mandate October 18, 2024

Vinge has advised Sveafastigheter in connection with its listing on Nasdaq First North Premier Growth Market

Vinge has advised Sveafastigheter AB (publ) (”Sveafastigheter”) in connection with its listing on Na…

Mandate October 07, 2024

Vinge advises iBinder Group in connection with the acquisition of Avima AB

Avima AB is a Swedish specialist in project and information management, with expertise in complex pr…

Mandate June 04, 2024

Vinge has assisted Priveq in connection with the formation of Priveq Investment VII

Priveq, a leading Nordic lower mid-market growth and buyout investor, has closed its seventh fund, P…

Mandate May 27, 2024

Vinge has advised Alder on the establishment of Alder III

Vinge has advised Alder on the establishment of Alder's third and largest fund to date, Alder III.

Mandate April 05, 2024

Vinge has advised Helix Kapital in connection with the fund formation of Helix Kapital Fund III

Vinge has advised Helix Kapital in the establishment of Helix Kapital’s third fund, Helix Kapital Fu…

Mandate February 21, 2024

Vinge advises Adelis Equity Partners on the establishment of a continuation fund

Vinge has advised Adelis Equity Partners on the establishment of a continuation fund to Adelis Equit…

Mandate October 18, 2023

Vinge advises Thermo Fisher in connection with the acquisition of Olink

Vinge has advised Thermo Fisher Scientific Inc., (”Thermo Fisher”), the world leader in serving scie…

Mandate September 15, 2023

Vinge advises Altor in connection with its acquisition of a significant minority stake in Marshall Group AB (publ)

Vinge advises the Altor Funds (“Altor”) in connection with its acquisition of a significant minority…

Mandate June 08, 2023

Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date

The fund – which is Fidelio Capital’s third – has secured more than EUR 1 billion in total capital c…

Mandate May 22, 2023

Vinge advises Tele2 in connection with its notes issuance and tender offer

Vinge advises Tele2 AB (publ) in connection with its issuance of senior unsecured fixed rate notes i…

Mandate April 11, 2023

Vinge has advised Procuritas in connection with the formation of their largest fund to date

The fund has received total commitments of EUR 407 million. Procuritas is a private equity firm focu…

Mandate February 01, 2023

Vinge advises Veeco Instruments Inc. in its acquisition of Epiluvac AB

Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisitio…

Mandate December 16, 2022

Vinge advises Acrinova AB (publ) in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s…

Mandate October 19, 2022

Vinge advises Night Train Media in connection with its acquisition of Eccho Rights

Vinge has advised the German company Night Train Media GmbH, part of the Serafin Group, in connectio…

Mandate June 30, 2022

Vinge has advised SBC Sveriges BostadsrättsCentrum with the acquisition of Mediator AB

Vinge has advised SBC Sveriges BostadsrättsCentrum, a all-round supplier within the residential real…

Mandate June 03, 2022

Vinge has advised VEF AB (publ) in connection with the listing of the company’s ordinary shares on Nasdaq Stockholm’s Main Market

Vinge has advised VEF AB (publ) in connection with its list change from Nasdaq First North Growth Ma…

Mandate December 09, 2021

Vinge has advised Tobii in connection with the listing of Tobii Dynavox

Vinge has advised Tobii and Tobii Dynavox in connection with the distribution of the shares in Tobii…

Mandate October 21, 2021

Vinge advises Isofol in connection with its listing on Nasdaq Stockholm

Vinge has advised Isofol Medical AB in connection with its listing on Nasdaq Stockholm, with the fir…

Mandate October 15, 2021

Vinge has advised Byggfakta in connection with its listing on Nasdaq Stockholm

The first day of trading on Nasdaq Stockholm large cap was 15 October 2021. The offer price was SEK…

Mandate October 06, 2021

Vinge advises eEducation Albert AB (publ) in connection with the listing on Nasdaq First North Growth Market6 October 2021

Vinge has advised eEducation Albert AB (publ) (”Albert”) in connection with its listing on Nasdaq Fi…

Mandate June 11, 2021

Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised Sdiptech AB (publ) in connection with its list change from Nasdaq First North Prem…

Mandate April 20, 2020

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised CELLINK AB (publ) in connection with its list change from Nasdaq First North Growt…

Mandate April 02, 2020

Vinge advises Isofol in conjunction with capital procurement

Vinge has advised Isofol Medical AB (publ), First North Growth Market Premier, in connection with it…

Mandate January 10, 2020

Vinge advises Latour Capital and Sulo on the acquisition of San Sac Group

Sulo is a leading international manufacturer of bins, underground and semi-underground systems for c…

Mandate September 24, 2019

Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm

Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockh…

Mandate September 23, 2019

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First N…

Mandate February 25, 2019

Vinge advises Vostok New Ventures Ltd

Vinge has advised Vostok New Ventures Ltd with capital markets related questions in light of the com…

Mandate December 04, 2018

Vinge advises Vicore Pharma in connection with a directed share issue

The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary ge…